Home Knowledge among clinical personnel on the impact of hemolysis using blood gas analyzers
Article Open Access

Knowledge among clinical personnel on the impact of hemolysis using blood gas analyzers

  • Trine Muhs Nielsen ORCID logo , Charlotte Gils EMAIL logo and Mads Nybo ORCID logo
Published/Copyright: December 11, 2024

Abstract

Objectives

In the light of a rapidly increasing use of POCT blood gas testing, where tests and interpretation are performed by non-laboratory personnel, the objective was to investigate the knowledge among personnel in the Nordic countries using blood gas analyzers with focus on the interference from hemolysis.

Methods

Information was obtained from a self-developed, pre-tested online questionnaire. The questions covered demographic information about the respondents and specific questions on handling of and knowledge about blood gas analyses and the impact of hemolysis. The questionnaire was distributed by e-mail to relevant colleagues on behalf of the Nordic preanalytical scientific working group under the Nordic Federation of Clinical Chemistry.

Results

A total of 117 respondents completed the questionnaire. 62.7 % respondents both used the analyzer and interpreted the results. 59.6 % respondents did not know to which degree the blood gas analyzer can identify hemolysis. 4.4 % answered that all levels or high levels of hemolysis can be detected. 3.9 % considered the result valid despite hemolysis if it is released from the instrument. 73.7 % of all respondents knew that hemolysis alters potassium measurements, while knowledge about the effect on PaO2 and bicarbonate measurements were more divergent.

Conclusions

The knowledge about blood gas analyzers with focus on the interference from hemolysis is sparse among non-laboratory personnel using the blood gas analyzers. This emphasizes the need for better education and competence management, which perhaps is even more important for these analyses than for other point-of-care tests.

Introduction

The preanalytical phase is important in laboratory diagnostics as several issues can affect the test results and their reliability. Previous studies have shown that in vitro hemolysis is the most prevalent preanalytical error [1]. Hemolysis is defined as rupture of erythrocytes and release of intracellular components into serum or plasma [1], 2]. It is well known that in vitro hemolysis can alter the measurement of potassium and other primarily intracellular substances to either false high or false normal results (in case of hypokalemia) [2], 3]. Conversely, extracellular substances will primarily be false decreased due to dilution [2], 3]. Furthermore, the released intracellular components can interfere with the chemical reaction used in the requested analysis, which can results in spectrophotometric interference as released hemoglobin absorbs light strongly at 415 nm, 540 nm, and 570 nm [3].

In many laboratories, sample integrity is checked by automated chemistry and immunochemistry equipment to assure that hemolysis, icterus and lipemia, respectively, does not interfere with the measurement of the requested analyses (HIL check) [4]. This is in accordance with ISO 15189:2022 stating that specified requirements of an examination method may include interfering substances [5]. However, interference from hemolysis in arterial blood samples for blood gas analyses may be just as common as in blood samples sent to core laboratories, and studies have indeed found hemolysis in up to 4–13 % of blood gas samples [6], [7], [8], [9], [10]. It is known that hemolysis in blood gas samples alter potassium measurements, whereas results on e.g. pH, HCO3, and pO2 are divergent [10], 11]. Sodium, Ca2+ and pCO2 has also been stated as prone to hemolysis [10]. Unfortunately, blood gas analyzers are unable to identify hemolysis, icterus and lipemia [10], and undetected hemolysis in blood samples for blood gas analysis can therefore lead to erroneous clinical interpretation and treatment.

Originally, blood gas analyzers only measured pO2, pCO2, pH, and SaO2 [12]. Today, the number of analyses included in “blood gas testing” have expanded considerably, and modern blood gas analyzers also perform rapid measurements of e.g. electrolytes, glucose, lactate, creatinine, and hemoglobin and are a key element in the swift clinical management of critically ill patients [13]. This underlines the need for valid test results, especially when the personnel responsible for the preanalytical and analytical phase are working outside the core laboratories. However, it is not well established what clinical and laboratory personnel know about the impact of hemolysis on blood gas analyses. Moreover, do they know what to be aware of and when? The aim of this study was to investigate the knowledge among clinical personnel on blood gas analyzers with focus on the interference from hemolysis.

Materials and methods

This questionnaire study was carried out from October 2022 to May 2024. The questionnaire consists of 13 questions covering demographic information about the respondents as well as specific questions on handling of and knowledge about blood gas analyses and hemolysis (see Table 1). Questions were adjusted in collaboration with the Nordic preanalytical scientific working group under the Nordic Federation of Clinical Chemistry (NFKK) and also tested by local anesthesiologists. The questionnaire was distributed to personnel handling the blood gas analyzers through the NFKK on behalf of the Nordic preanalytical scientific working group under NFKK.

Table 1:

All the questions in the survey.

1. Please type your title % (%)
Medical doctor 37 (31.6)
Chemist or medical doctor at laboratory department 17 (14.5)
Other 56 (47.9)
Not specified 7 (6.0)
2. Please type your place of employment % (%)
Intensive care unit 38 (32.5)
Clinical department including emergency department 33 (28.2)
Pediatric department 5 (4.3)
Other 15 (12.8)
Not specified 26 (22.2)
3. Please type your country % (%)
Denmark 52 (44.4)
Sweden 22 (18.8)
Finland 13 (11.1)
Norway 2 (1.7)
Not specified 28 (23.9)
4. Your knowledge about the blood gas analyzer % (%)
I “just” use the instrument 7 (6.0)
I use the analyzer, and I interpret the results 74 (63.2)
I use the analyzer, I interpret the results, and I have a deeper knowledge about the analyzer 36 (30.8)
5. Type of blood gas analyzer you use? a % (%)
Radiometer, ABL 79 (67.5)
Siemens epoc 2 (1.7)
Siemens (other) 6 (5.1)
I do not know 27 (23.1)
Other 6 (5.1)
Not specified 1 (0.9)
6. Do you assess the quality of a blood sample before you analyze it? % (%)
Yes 84 (71.2)
No 30 (25.4)
I do not know 4 (3.4)
7. If yes to question 6, how do you assess the quality? % (%)
Air bubbles 36 (42.9)
Volume 28 (33.3)
Clots 25 (29,8)
Other 59 (70.2)
8. To which degree can your blood gas analyzer identify hemolysis? % (%)
All levels of hemolysis can be detected 4 (3.5)
Only high levels of hemolysis can be detected 1 (0.9)
The instrument does not mark for hemolysis 41 (36.0)
I do not know 68 (59.6)
9. Does your blood gas analyzer indicate for hemolysis on any test results? If yes, how is it marked? % (%)
There is no indication of hemolysis 48 (43.6)
It is indicated in the laboratory information system 1 (0.9)
It is indicated in the patient’s medical record 0 (0.0)
It is indicated on a print from the blood gas analyzer 7 (6.4)
I do not know 54 (49.1)
10. Action taking in the presence of hemolysis on any test results from your blood gas analyzer? % (%)
If the result is released from the analyzer, it is considered valid despite of hemolysis 4 (3.9)
The result might be biased but can be used as an indicator of the clinical condition of the patient 5 (4.9)
The result is not valid and another arterial blood sample must be collected 35 (34.0)
Because of hemolysis, venipuncture is performed instead 0 (0.0)
The clinical biochemistry department is contacted for consultation 3 (2.9)
There is no indication of hemolysis from the analyzer 44 (42.7)
Another option than those mentioned 12 (11.7)
11. Do you believe that hemolysis has any clinical impact on any PaO2 measurement on the analyzer? % (%)
Not at all 9 (7.9)
To some degree 29 (25.4)
Very much 18 (15.8)
It depends on the sample material (arterial, venous etc.) 6 (5.3)
I do not know 52 (45.6)
12. Do you believe that hemolysis has any clinical impact on any bicarbonate measurement on the analyzer? % (%)
Not at all 6 (5.2)
To some degree 32 (27.6)
Very much 13 (11.2)
It depends on the sample material (arterial, venous etc.) 2 (1.7)
I do not know 63 (54.3)
13. Do you believe that hemolysis has any clinical impact on any potassium measurement on the analyzer? % (%)
Not at all 0 (0.0)
To some degree 20 (16.5)
Very much 70 (57.8)
It depends on the sample material (arterial, venous etc.) 2 (1.7)
I do not know 29 (24.0)
  1. aPercentages more than 100 % as multiple answers are possible.

To elucidate the knowledge about interference of hemolysis in blood gas specimens among personnel responsible for interpretation of the results, a subgroup analysis on medical doctors working outside the core laboratories was performed.

No formal ethical approval was necessary as respondents were anonymous and no patient data was used.

Results

In total, 117 respondents completed the questionnaire. See Table 1 for background characteristics. Of all respondents, 37 (31.6 %) were medical doctors working outside the core laboratory. Most respondents (63.2 %) both used the analyzer and interpreted the result. In the subgroup of medical doctors working outside the core laboratories, 97.3 % interpreted the results (data not shown). A minority of 36 (30.8 %) of all respondents declared also to have a deeper understanding about the blood gas analyzer (Table 1).

The majority, 84 (71.8 %) of the respondents, assessed the quality of a blood sample before they analyzed it, whereas 30 (25.6 %) did not (Table 1). Among medical doctors working outside the core laboratories, 23 (62.2 %) assessed the quality of the blood sample before they analyzed it (Figure 1), while 12 (32.4 %) did not. The remainder did not answer the question (data not shown). Results on how the yes-respondents assessed the quality of the blood samples are presented in Figure 1.

Figure 1: 
How do you assess the quality? (Yes-responders, question 6)*. Total: n=84 medical doctors: n=23. Number of respondents are indicated as small numbers. *Percentages sum to more than 100 % as multiple answers are possible.
Figure 1:

How do you assess the quality? (Yes-responders, question 6)*. Total: n=84 medical doctors: n=23. Number of respondents are indicated as small numbers. *Percentages sum to more than 100 % as multiple answers are possible.

When focusing on the ability of the blood gas analyzer to identify hemolysis (question 7, 8 and 9), 68 (59.6 %) did not know to which degree the blood gas analyzer can identify hemolysis, whereas four respondents (3.5 %) answered that all levels or high levels of hemolysis can be detected (Table 1). Four respondents (3.9 %) considered the result valid despite hemolysis if it is released from the instrument. Many respondents did know that there is no indication of hemolysis from the analyzer (n=44), but a comparable number did not know whether the analyzer do flag for hemolysis or not (n=54) (Table 1).

Knowledge about how hemolysis affects the measurements on the blood gas analyzer; 84 (73.7 %) of all respondents and 35 (97.2 %) of the medical doctors knew that hemolysis alters potassium measurements very much or to some degree (Figure 2). Knowledge about the effect on PaO2 and bicarbonate measurements were more divergent as shown in Figure 2.

Figure 2: 
Do you believe that hemolysis has any clinical impact on PaO2/bicarbonate/potassium measurement on the analyzer? (Question 11–13). Total: n=114 for PaO2 and potassium, n=116 for bicarbonate. Medical doctors: n=36.
Figure 2:

Do you believe that hemolysis has any clinical impact on PaO2/bicarbonate/potassium measurement on the analyzer? (Question 11–13). Total: n=114 for PaO2 and potassium, n=116 for bicarbonate. Medical doctors: n=36.

Discussion

In this survey among 117 clinical and laboratory personnel in four Nordic countries, we found that less than a third of respondents declared to have a deeper understanding about the blood gas analyzer. This is in line with the finding that most of the respondents do not know to which degree the blood gas analyzer can identify hemolysis. Likewise, almost half of all respondents and more than 80 % of the medical doctors did not know if the blood gas analyzer indicates for hemolysis. Furthermore, assessment of the blood sample quality prior to analysis was very heterogeneous and in general insufficient.

To our knowledge, this is the first survey with focus on clinical personnel and their knowledge about hemolysis in blood gas analyses, and it rises several issues to address.

Clinical impact

Most medical doctors participating in this survey, of whom almost all interpret the analysis results, knew that hemolysis alter the measured potassium concentration. However, only 25.7 % of the medical doctors knew that the blood gas analyzers do not flag for hemolysis. Although most of the respondents (71.8 %) declared to assess the sample quality, this still leaves over 25 % that does not. Furthermore, most of the respondents assessing the sample quality did not look for air bubbles, sample volume or clots before analyzing the sample. Clotting and insufficient volume are well-described preanalytical errors, and bubbles can significantly alter analyte concentrations in blood gas measurements [12]. Thus, even though the respondents declare to assess the quality of the blood samples, this evaluation seems inadequate to reveal all preanalytical errors. Consequently, if the medical doctors responsible for patient’s care are not aware of potential hemolysis and other preanalytical errors, they risk relying on the results released from the instrument, which could lead to erroneous conclusions. Of particular note is the finding that four respondents considered the result valid despite hemolysis if it was released from the instrument. This could be critical and ultimately lead to wrong treatment of the patients. Supporting this, ±8 % of all paired potassium results analyzed on blood gas analyzer and core laboratories in a recent multicenter study were outside the reference change value, indicating a risk of incorrect diagnosis and subsequently incorrect clinical care of the patients in emergency departments [14]. The importance of all these aspects is emphasized by the fact that POCT are used incrementally due to a wish for faster patient flow and a swifter handling of alarming situations – a necessity that increases the importance of a robust and reliable test result: The faster the action, the more important the reliability of the test result upon which the action is based. The increasing use and organizational reliability on POCT result therefore stresses the need for better knowledge about the different caveats and pitfalls in POCT measurements in general.

How to improve

Our study identified a limited knowledge on blood gas analyzers among personnel responsible for blood gas testing and interpretation. This indicates a need for improved education of the personnel handling the blood gas analyzers. The ISO 15189:2022 states that ‘The laboratory shall specify the competence requirements for each function influencing the results of laboratory activities, including requirements for education, qualification, training, re-training, technical knowledge, skills and experience’ and ‘The laboratory shall have a process for managing competence of its personnel, that includes requirements for frequency of competence assessment’ [5]. Furthermore, it is stated that an appropriate theoretical and practical training program for all POCT personnel should be developed and implemented [5]. Managing competences of the personnel handling the blood gas analyzers is however complex as the instruments and the staff performing the POCT measurements primarily are located outside the core laboratories. A well-organized POCT organization and the implementation of user management is a necessity to solve this problem. User management implies education and competence assessment of the relevant staff, which is a huge, but very important task for the laboratories to fulfil. It is crucial that this is supported by the hospital administration and adheres to relevant international guidelines and as of lately the updated ISO 15189:2022, which now has included the POCT area on behalf of the former ISO 22870. In addition, the updated ISO 15189:2022 requires performance of risk assessment. The laboratory is required to identify potential risks to patient care in the pre-examination, examination and post-examination processes. This includes risk assessment of the use of POCT. For this purpose, a risk analysis model to diminish negative impact on patient care by preanalytical errors in blood gas analysis has been proposed [15]. This model is based on identification of errors that may occur while performing blood gas analysis, possible consequences and preventive actions [15].

Another possible improvement area is e-learning and audit as known from the blood sampling area: Willman et al. evaluated a large-scale online e-learning program on venous blood specimen collection with promising results [16]. An e-learning program on blood gas analysis may also improve the whole testing process of blood gasses, including the preanalytical phase and the external staff responsible for these analyses [16]. Another option is the use of an observation scheme or checklist for quality control as suggested for phlebotomy by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase [17]. Introduction of an observation scheme in blood gas testing may also improve the preanalytical phase in this area. Within the context of improvement, it would be interesting to provide a follow-up survey focusing on the effect of education of POCT users outside of core laboratories.

Today, sample integrity check generally is performed by automated chemistry and immunochemistry equipment in many laboratories. As shown in this survey, some clinicians responsible for interpreting the analysis results are used to lab results without preanalytical flaws (unless clearly stated along with the results), and despite differences in skills of the performing staff, the expectation for flawless results are clearly the same. It is therefore mandatory to consider, how it is technically possible to qualify POCT results besides optimizing the education as mentioned. Casati et al. [10] proposed to introduce automated processing of serum indices in blood gas analyzers, and Buno et al. also stated that technological improvements are desirable [18], as they will ensure that hemolysis, icterus and lipemia does not interfere with the measurements. As an alternative, a photometric hemolysis detection system intended for use with POCT has shown promising results [19]. These are all options that the laboratories need to take into consideration to minimize the risk of decision-making based on erroneous test results.

Strengths and limitations

A limitation of the study is the use of a non-validated questionnaire. However, to our knowledge no validated questionnaire exists in this area. Furthermore, the questionnaire was adjusted and improved in collaboration with members of the Nordic preanalytical scientific working group under NFKK, and finally, the questionnaire was tested on local anesthesiologists to ensure a user-friendly design and appropriate questioning.

As the questionnaire was distributed widely, we have no knowledge about the non-responders. Consequently, we do not know if respondents are representative of the targeted population. However, we have respondents from four Nordic countries indicating the problem to be general and not limited to one hospital or country. The laboratory departments in the Nordic countries are generally well-organized with well-functioning POCT organizations. Furthermore, the hospitals are very similar. Thus, we assume our results to be representative of the hospitals in the Nordic countries. We can only speculate if the results can be extrapolated to other countries, but as stated, many of the observations and challenges are compatible with previous European studies within this area, so our qualified guess is that it can be extrapolated at least to other European countries.

Conclusions

The knowledge about blood gas analyzers with focus on the interference from hemolysis is sparse among extra-laboratory personnel using the blood gas analyzers. This emphasizes the need for better education and competence management when personnel working outside the core laboratories are responsible for the preanalytical and analytical phase of laboratory testing. Also, technical solutions that can ensure the preanalytical handling and sample integrity are warranted. The literature in this area is generally sparse, and more research with focus on the knowledge of blood gas analysis among end-users is warranted. As many blood samples for blood gas analyses are handled outside the core laboratories by clinical personnel, our study enlightens an area with great potential for improvement.


Corresponding author: Charlotte Gils, Department of Clinical Biochemistry, Odense University Hospital, J. B. Winsløws Vej 4, 5000 Odense, Denmark, E-mail:

Acknowledgments

We thank the Preanalytic scientific working group under the NFKK and all respondents for their contribution to this study.

  1. Research ethics: Not applicable.

  2. Informed consent: Not applicable.

  3. Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: The raw data can be obtained on request from the corresponding author.

References

1. Lippi, G, Luca Salvagno, G, Blanckaert, N, Giavarina, D, Green, S, Kitchen, S, et al.. Multicenter evaluation of the hemolysis index in automated clinical chemistry systems. Clin Chem Lab Med 2009;47:934–9. https://doi.org/10.1515/cclm.2009.218.Search in Google Scholar

2. Heireman, L, Van Geel, P, Musger, L, Heylen, E, Uyttenbroeck, W, Mahieu, B. Causes, consequences and management of sample hemolysis in the clinical laboratory. Clin Biochem 2017;50:1317–22. https://doi.org/10.1016/j.clinbiochem.2017.09.013.Search in Google Scholar PubMed

3. Lippi, G, Blanckaert, N, Bonini, P, Green, S, Kitchen, S, Palicka, V, et al.. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 2008;46:764–72. https://doi.org/10.1515/cclm.2008.170.Search in Google Scholar

4. Cadamuro, J, Lippi, G, von Meyer, A, Ibarz, M, van Dongen, E, Lases, et al.. European survey on preanalytical sample handling – part 2: practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples. Biochem Med 2019;29:020705. https://doi.org/10.11613/BM.2019.020705.Search in Google Scholar PubMed PubMed Central

5. International Organization for Standardization. Medical laboratories – requirements for quality and competence, 4th ed. Geneva: ISO 15189; 2022.Search in Google Scholar

6. Lippi, G, Ippolito, L, Fontana, R. Prevalence of hemolytic specimens referred for arterial blood gas analysis. Clin Chem Lab Med 2011;49:931–2. https://doi.org/10.1515/cclm.2011.136.Search in Google Scholar

7. Wilson, A, Sweeney, M, Mark Lynch, PL, O’Kane, MJ. Hemolysis rates in whole blood samples for blood gas/electrolyte analysis by point-of-care testing. J Appl Lab Med 2018;3:144–5. https://doi.org/10.1373/jalm.2018.026427.Search in Google Scholar PubMed

8. Nigro, M, Valli, G, Marchionne, ML, Sattarinia, D, Silvestrini, F, De Pietro, D, et al.. Is there a risk of misinterpretation of potassium concentration from undetectable hemolysis using a POCT blood gas analyzer in the emergency department? Medicina 2022;59:66. https://doi.org/10.3390/medicina59010066.Search in Google Scholar PubMed PubMed Central

9. Salvagno, GL, Lippi, G, Gelati, M, Guidi, GC. Hemolysis, lipaemia and icterus in specimens for arterial blood gas analysis. Clin Biochem 2012;45:372–3. https://doi.org/10.1016/j.clinbiochem.2011.12.005.Search in Google Scholar PubMed

10. Casati, M, Intra, J, Rossi, W, Giacobone, C, Brivio, R. Hemolysis and blood gas analysis: it’s time for a change!. Scand J Clin Lab Invest 2022;82:138–42. https://doi.org/10.1080/00365513.2022.2034037.Search in Google Scholar PubMed

11. Lippi, G, Fontana, R, Avanzini, P, Sandei, F, Ippolito, L. Influence of spurious hemolysis on blood gas analysis. Clin Chem Lab Med 2013;51:1651–4. https://doi.org/10.1515/cclm-2012-0802.Search in Google Scholar PubMed

12. Baird, G. Preanalytical considerations in blood gas analysis. Biochem Med 2013;23:19–27. https://doi.org/10.11613/bm.2013.005.Search in Google Scholar PubMed PubMed Central

13. Zwisler, ST, Zincuk, Y, Bering, CB, Zincuk, A, Nybo, M, Mikkelsen, S. Diagnostic value of prehospital arterial blood gas measurements - a randomised controlled trial. Scand J Trauma Resuscitation Emerg Med 2019;27:32. https://doi.org/10.1186/s13049-019-0612-8.Search in Google Scholar PubMed PubMed Central

14. Tintu, AN, Soto, AB, Van Hoof, V, Bench, S, Malpass, A, Schilling, UM, et al.. The influence of undetected hemolysis on POCT potassium results in the emergency department. CCLM 2024;62:2169–76.10.1515/cclm-2024-0202Search in Google Scholar PubMed

15. Van Hoof, V, Bench, S, Soto, AB, Luppa, P, Malpass, A, Schilling, UM, et al.. Failure mode and effects analysis (FMEA) at the preanalytical phase for POCT blood gas analysis: proposal for a shared proactive risk analysis model. CCLM 2022;60:1186–201. https://doi.org/10.1515/cclm-2022-0319.Search in Google Scholar PubMed

16. Willman, B, Grankvist, K, Bolenius, K. Evaluation of the clinical implementation of a large-scale online e-learning program on venous blood specimen collection guideline practices. Clin Chem Lab Med 2018;56:1870–7. https://doi.org/10.1515/cclm-2018-0051.Search in Google Scholar PubMed

17. Seemann, TL, Nybo, M. Continuous quality control of the blood sampling procedure using a structured observation scheme. Biochem Med 2016;26:337–45. https://doi.org/10.11613/bm.2016.037.Search in Google Scholar

18. Buno, A, Oliver, P. POCT errors can lead to false potassium results. Adv Lab Med 2022;3:142–52. https://doi.org/10.1515/almed-2021-0079.Search in Google Scholar PubMed PubMed Central

19. Duhalde, H, Skogo, J, Karlsson, M. Point-of-care hemolysis detection in blood gas specimens directly at the emergency department. Scand J Clin Lab Invest 2019;79:283–7. https://doi.org/10.1080/00365513.2019.1612089.Search in Google Scholar PubMed

Received: 2024-08-30
Accepted: 2024-12-01
Published Online: 2024-12-11
Published in Print: 2025-04-28

© 2024 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Are the benefits of External Quality Assessment (EQA) recognized beyond the echo chamber?
  4. Reviews
  5. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part I – EQA in general and EQA programs in particular
  6. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part II – EQA cycles
  7. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part III – EQA samples
  8. Behind the scenes of EQA–characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part IV – Benefits for participant laboratories
  9. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part V – Benefits for stakeholders other than participants
  10. Opinion Papers
  11. Not all biases are created equal: how to deal with bias on laboratory measurements
  12. Krebs von den Lungen-6 (KL-6) as a diagnostic and prognostic biomarker for non-neoplastic lung diseases
  13. General Clinical Chemistry and Laboratory Medicine
  14. Evaluation of performance in preanalytical phase EQA: can laboratories mitigate common pitfalls?
  15. Point-of-care testing improves care timeliness in the emergency department. A multicenter randomized clinical trial (study POCTUR)
  16. The different serum albumin assays influence calcium status in haemodialysis patients: a comparative study against free calcium as a reference method
  17. Measurement of 1,25-dihydroxyvitamin D in serum by LC-MS/MS compared to immunoassay reveals inconsistent agreement in paediatric samples
  18. Knowledge among clinical personnel on the impact of hemolysis using blood gas analyzers
  19. Quality indicators for urine sample contamination: can squamous epithelial cells and bacteria count be used to identify properly collected samples?
  20. Reference Values and Biological Variations
  21. Biological variation of cardiac biomarkers in athletes during an entire sport season
  22. Increased specificity of the “GFAP/UCH-L1” mTBI rule-out test by age dependent cut-offs
  23. Cancer Diagnostics
  24. An untargeted metabolomics approach to evaluate enzymatically deconjugated steroids and intact steroid conjugates in urine as diagnostic biomarkers for adrenal tumors
  25. Cardiovascular Diseases
  26. Comparative evaluation of peptide vs. protein-based calibration for quantification of cardiac troponin I using ID-LC-MS/MS
  27. Infectious Diseases
  28. The potential role of leukocytes cell population data (CPD) for diagnosing sepsis in adult patients admitted to the intensive care unit
  29. Letters to the Editor
  30. Concentrations and agreement over 10 years with different assay versions and analyzers for troponin T and N-terminal pro-B-type natriuretic peptide
  31. Does blood tube filling influence the Athlete Biological Passport variables?
  32. Influence of data visualisations on laboratorians’ acceptance of method comparison studies
  33. An appeal for biological variation estimates in deep immunophenotyping
  34. Serum free light chains reference intervals for the Lebanese population
  35. Applying the likelihood ratio concept in external quality assessment for ANCA
  36. A promising new direct immunoassay for urinary free cortisol determination
Downloaded on 11.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2024-1018/html
Scroll to top button